Fenwick represented Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, in its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $30.00 per share. The net proceeds to Veracyte from the offering were approximately $194 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Goldman Sachs & Co., LLC and SVB Leerink LLC acted as joint lead book-running managers for the offering. William Blair & Company, L.L.C. acted as a book-running manager and BTIG, LLC, Needham & Company, LLC, and Lake Street Capital Markets, LLC acted as co-managers.
More information can be obtained from Veracyte’s announcement.
The Fenwick transaction team included corporate partner Ran Ben-Tzur, senior attorney Soo Hwang and associate Alyssa Zhang.